Searchable abstracts of presentations at key conferences in endocrinology

ea0035p800 | Paediatric endocrinology | ECE2014

Small for gestational age (SGA) children: Results after 3 years of GH therapy

Galesanu Corina , Loghin Andra , Grozavu Ilinka , Condrea Adrian , Ungureanu Didona

Introduction: GH therapy (rhGH) improves growth outcome in children born small for gestational age (SGA). Growth velocity is maximum in the first year of therapy. Early diagnosis and treatment optimizes the final height.Objectives: Evaluation of efficacy and safety profile in the first 3 years of rhGH treatment in ten SGA children.Methods: The study enrolled ten SGA children (6 boys, 4 girls). All patients were given a mean dose of...

ea0032p843 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

The results of sandostatin LAR therapy in acromegalic patients

Galesanu Corina , Grozavu Ilinka , Loghin Andra , Florescu Alexandru , Haba Danisia

Introduction: Somatostatin analogs, formerly used as adjuvants in acromegaly treatment, are widely used as primary treatment today.Objective: To investigate the efficacy of octreotide therapy in acromegalic patients as primary or secondary therapy.Materials and methods: Four acromegalic patients diagnosed at the Endocrinological Clinic (males, mean age 35–75 years, age range 26–49 years, all patients with macroadenoma) we...

ea0029p194 | Bone &amp; Osteoporosis | ICEECE2012

Zoledronic acid treatment improve bone strenght parameters assessed by BMD

Galesanu C. , Loghin A. , Florescu A. , Lisnic N. , Aancute P. , Zaharia V.

Introduction: Bisphosphonates therapy is the standard of care in postmenopausal osteoporosis. In the HORIZON-RFT, annual i.v. Zoledronic acid (ZOL) 5 mg infusion significantly reduced the rate of new fractures by increased bone mineral density (BMD). We proposed to evaluate the effect of ZOL treatment in BMD change in a group of postmenopausal osteoporotic women assessed by DXA–BMD. We have proposed also to assess the adverse events of this treatment.<p class="abstext...

ea0029p394 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Giant macroprolactinoma: recidive after 12 years (case report)

Loghin A. , Florescu A. , Grozavu I. , Haba D. , Apostu L. , Galesanu C.

Introduction: Prolactinomas are rare in childhood and adolescence, representing a half of pituitary adenomas (1% of intracranial tumors); macroadenomas are more frequent than microadenomas. The signs and symptoms depend on age, sex, tumor size and prolactin level. Due to a higher frequency of macroadenomas in boys, they present more often neuro-ophthalmologic findings (impaired vision, headache)Case report: We present a case of 25-year-old pacient diagno...

ea0029p397 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Macroprolactinomas: therapy compliance (case report)

Florescu A. , Loghin A. , Grozavu I. , Haba D. , Apostu L. , Galesanu C.

Prolactinomas represent 60% of primary pituitary tumors, galactorrrhoea and menstrual disturbances beeing the most frequent clinical features in women. The mass effect of macroadenomas is expressed by headache, visual field defects and hypopituitarism. The aims of therapy are reduction of tumour size, prevention of tumour expansion and restoration of gonadal function. Dopamine agonists normalize prolactin secretion and reduce tumour size in 40% of patients with macroadenoma.</...

ea0026p525 | Bone/calcium/Vitamin D | ECE2011

Efficacy of Alendronate treatment in women with postmenopausal osteoporosis: results after 3-year study

Natalia Lisnic , Alexandru Florescu , Iulia Loghin Andra , Corina Galesanu

Introduction: In Romania, the prevalence of postmenopausal osteoporosis in urban centers was estimated by a study in 2007 to be 16.5%. Using alendronate we are increasing bone mineral density and reducing bone turn-over in women with postmenopausal osteoporosis.Materials and methods: There were examined 55 postmenopausal women with osteoporosis (average age 62±4.5 years). Bone mineral density (BMD) was determined by dual-energy X-ray absorptiometer ...

ea0026p526 | Bone/calcium/Vitamin D | ECE2011

Bisphosponates therapy in women with post-menopausal osteoporosis: comparative results

Corina Galesanu , Alexandru Florescu , Andra Iulia Loghin , Natalia Lisnic

Aim: To evaluate the effect of risedronate vs ibandronate in treatment of systemic osteoporosis in postmenopausal women.Materials and methods: We examined 57 postmenopausal women with systemic osteoporosis (average age 61±3.5 years). Bone mineral density (BMD) was determined by dual-energy X-ray absorptiometer (HOLOGIC Delphi W; SN 7044909) on lumbar spine. Examination was performed before the onset of treatment and after a period of 1, 2 and 3 year...

ea0026p606 | Clinical case reports | ECE2011

Primary hypothyroidism due to sublingual thyroid associated with growth failure, hyperprolactinemia and pituitary enlargement

Loghin A , Florescu A , Moisii L , Stefanescu C , Galesanu C

Introduction: Thyroid tissue may be found anywhere along the course of thyroglossal duct. Sublingual thyroid is a rare type of ectopic thyroid tissue resulting from failure of the embryonic development and migration of the thyroid gland to its normal pre-laryngeal site, reaching between genio-hioid and mylohyiod muscles. In most cases, hypothyroidism develops due to inadequate hormon production. Hypothyroidism may produce pituitary enlargement secondary to thyrotroph hyperplas...